November 18, 2021 7:54am
Where and what are the coefficients of share pricing appreciation as markets point to a higher open?
Pre-open indications: 6 SELLs, 2 BUY and 1 Pump (or No Promote)
If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing!
Remember that overnight and pre-open actions in futures doesn't necessarily translate into actual trading in the coming day’s session.
I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”
Dow futures are UP +0.09% (+32 points), S&P futures are UP +0.26% (+12 point) and NASDAQ futures are UP +0.53% (+86 points)
U.S. stock futures were fractionally higher in premarket trading on Thursday,
European stocks were mixed and basically flat,
Asia-Pacific markets traded mixed
Henry’omics:
On Wednesday, the Dow lost 211 points or -0.58%, the S&P 500 dived -12.23 points or -0.26%, the Nasdaq fell -52.28 points or -0.33% lower while the small-cap benchmark Russell 2000 was the relative underperformer tumbling 1.2%.
Some investors might love biotech stocks for their lottery ticket-like returns when a company strikes medical gold. A lottery ticket, however, costs only a buck or two, while getting a biotech company wrong can hurt a lot more than that.
Economic Data Docket: The Labor Department will report last week’s jobless claims data at 8:30 a.m. Economists are expecting initial filings for unemployment insurance fell to 260,000 for the week ending November 13, from the previous week’s 267,000 claims.
If you didn’t remember what happen at Wednesday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:
Wednesday’s evening’s recap: “sentiment’s headwinds obliterate sector’s share pricing. Uncertainty as earnings drag share pricing and revenues drag as runways remain static.” … https://www.regmedinvestors.com/articles/12188
Q4: November, 3 positive and 10 negative close to date
- October, 8 positive and 13 negative closes
Companies in my headlights – It’s your decision; I provide an idea and context:
Maintaining SELL with a Pump or No Promote:
Biostage (BSTG) closed FLAT with 2,889 shares traded after Tuesday’s +$0.39 to $2.99 after Monday’s FLAT at $2.60 with 35 shares traded after Friday’s 0 shares traded and last Thursday’s -$0.22 to $2.60 with 2,005 shares traded.
- Earnings release: Biostage (BSTG) had a net loss of -$800 K, or -$0.80, a $200 K decrease in grant income and a cash position of $2 m—still with NO clinical trial with a 2-year-old IND. Add in some legal negligence ... where its insurance carrier will NOT cover the terminal death suit filed.
What’s there to invest in – the “Sword of Damocles” hanging over its recent insurance company rejection of legal expense/costs of a terminal death suit against the company?
- For a company with NO clinical trial, an a one (1) and a half year approved IND, four (4) employees and NO CRO <clinical research organization> initiation.
Probabilities versus aftermarket/pre-open share pricing indication moves:
BUY:
Ionis Pharmaceuticals (IONS) closed down -$0.19 to $32.48 with a positive +$1.42 or +0.68% pre-open indication.
Regenxbio (RGNX) closed down -$0.35 to $31.49 after Tuesday’s $31.84 and Monday’s $31.72 with a positive +$0.16 or +0.51% pre-open indication.
SELL from BUY:
Mesoblast (MESO) closed up +$0.23 to $6.65 after Tuesday’s -$0.67 to $6.42 with a negative -$0.25 or -3.76% pre-open indication.
SELL:
Sangamo Therapeutics (SGMO) closed down -$0.28 to $9.52 after Tuesday’s $9.80 and Monday’s $9.82 with a negative -$0.20 or -2.10% pre-open indication.
uniQure NV (QURE) closed down -$1.13 to $29.93after Tuesday’s $31.06 and Monday’s $31.08 with a negative -$0.50 or -1.67% pre-open indication.
Verastem (VSTM) closed down -$0.05 to $3.15 after Tuesday’s $3.20 and Monday’s $3.11 with a negative -$0.09 or -2.86% pre-open indication.
SELL into Strength:
Applied Genetic Technologies (AGTC) closed up +$0.29 to $2.66 with a positive +$0.05 or +1.88% pre-open indication.
BioLife Solutions (BLFS) closed down -$0.8 to $51.71 after Tuesday’s +$2.95 to $52.19 with a negative -$0.96 or -1.86% pre-open indication.
The BOTTOM LINE: Ten (10) session dives; are we set for more – I’d wait until Monday, as Thursday just might be a marginal up day and if Friday increases the beginning of inclines.
The coefficient (mentioned in title) is regulated by volume and its low and lower …
- Monday … Sector volume LOW with 2 of the 13-upside having higher than the 3-month average volume with LOW volume of 5 of 19-downside having higher than the 3-month average volume;
- Tuesday … Sector volume LOW with 3 of the 16-upside having higher than the 3-month average volume with LOW volume of 5 of 18-downside having higher than the 3-month average volume;
- Wednesday … Sector volume LOW with 1 of the 6-upside having higher than the 3-month average volume with LOW volume of 5 of 25-downside having higher than the 3-month average volume;
We are seeing to date, two (2) net income – Bellicum Pharmaceuticals (BLCM) and BioLife Solutions (BLFS)
- Twenty-one (25) net losses to date … Earning’s releases that initiated Q3 reporting season began the tug-of-war between share pricing that is softer than usual and the usual LPS (loss-per-share) to be less than estimates and expectations.
The stem, cell and gene therapy earnings continue with coming 11/15 (to date with more coming).
I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
